Humana Earnings Call Transcripts
Fiscal Year 2026
-
Performance is on track with expectations, supported by cost control, margin expansion, and operational improvements. Stars program progress and value-based care are driving quality and financial results, while strategic divestitures and capital initiatives enhance flexibility.
-
First quarter results met expectations, with strong MA and Medicaid membership growth and prudent reserving. Progress continues toward a 3%+ margin by 2028, aided by operational efficiencies, cost management, and strategic acquisitions.
-
The meeting covered director elections, auditor ratification, executive compensation, and a shareholder proposal on golden parachutes, which was not approved. Strategic updates highlighted a multi-year plan to restore margins, expand Medicaid and CenterWell, and simplify the member experience.
-
Margin restoration and earnings targets remain on track, with benefit adjustments and member retention prioritized. Membership growth is strong, driven by high-quality switchers and optimized sales channels. Regulatory changes and strategic acquisitions are being managed to support long-term profitability.
Fiscal Year 2025
-
Solid 2025 results with adjusted EPS of $17.14 and strong MA membership growth set the stage for 2026, despite a $3.5B Stars headwind and conservative guidance. Transformation, capital efficiency, and value-based care drive long-term margin and earnings potential.
-
The business is undergoing a major transformation, focusing on profitable growth, high-value distribution, and stable product offerings. Early retention and growth data are positive, with tightened margins and proactive risk management. Updates on membership and financials will be provided as warranted.
-
Third quarter results were solid, with revenue and medical cost trends in line with expectations and full year 2025 EPS outlook reaffirmed at ~$17. Membership retention and favorable product mix are driving growth, while transformation and operational efficiency initiatives continue.
-
Second quarter and first half results exceeded expectations, driven by CenterWell Pharmacy and improved MA membership trends. Full-year 2025 adjusted EPS outlook was raised to ~$17, with continued investment in member outcomes and operational excellence.
-
A multi-year transformation aims to become a consumer healthcare company, focusing on clinical excellence, operating leverage, and member retention. 2028 earnings are projected to be higher, with conservative stars assumptions and major investments in CenterWell and Medicaid. Margin improvement, benefit stability, and efficiency are central to the strategy.
-
Q1 2025 results exceeded expectations, driven by timing-related factors and strong CenterWell performance. Full-year guidance and adjusted EPS of $16.25 were reaffirmed, with robust growth in Medicare, Medicaid, and value-based care. Margin targets and operational progress remain on track.
Fiscal Year 2024
-
Adjusted EPS for 2024 met guidance, with margin recovery and operational improvements prioritized for 2025. Membership growth, plan exits, and Medicaid expansion drive segment performance, while regulatory and Stars-related uncertainties remain key risks.
-
Q3 results exceeded expectations, with stable medical costs and strong MA membership growth. 2024 EPS is on track, and 2025 guidance will balance investment in Stars and operational efficiency with at least flat performance. Stars ratings, regulatory changes, and Medicaid redetermination remain key risks.
-
Utilization and cost trends have stabilized, with inpatient pressures offset by positive claims development and risk scores. Plan exits will impact membership but are focused on unprofitable segments, while high-performing plans are protected. Conservative approaches to Part D and Medicaid are expected to support future margin improvement.
-
Second quarter results exceeded expectations, driven by strong Medicare growth and lower benefit ratios, though higher inpatient costs persist. Full-year guidance is reaffirmed, with ongoing mitigation efforts and a focus on multi-year margin recovery and cost discipline.